Biomarkers in Genitourinary Cancers: Volume I
Author: Eric A. Singer
Publisher: Frontiers Media SA
Published: 2022-05-25
Total Pages: 226
ISBN-13: 2889762157
DOWNLOAD EBOOKRead and Download eBook Full
Author: Eric A. Singer
Publisher: Frontiers Media SA
Published: 2022-05-25
Total Pages: 226
ISBN-13: 2889762157
DOWNLOAD EBOOKAuthor: Riccardo Tellini
Publisher: Frontiers Media SA
Published: 2022-11-14
Total Pages: 305
ISBN-13: 2832505376
DOWNLOAD EBOOKAuthor: Seyed Mohammad Kazem Aghamir
Publisher: Academic Press
Published: 2022-01-30
Total Pages: 210
ISBN-13: 0323983979
DOWNLOAD EBOOKLiquid Biopsy in Urogenital Cancers and Their Clinical Utility presents updated information on liquid biopsy techniques and their utility for diagnosing urological cancers. As a promising and recent diagnostic method, these techniques can be used for identifying tumors at initial stage, thus greatly improving treatment outcomes and survivorship. Chapters provide an overview of liquid biopsy as a new tool for diagnosis, monitoring and personalized medicine in urogenital cancers and explain its applicability in different cancer types, including bladder, prostate, kidney and testis tumors, female genital tract and pediatric urogenital tumors. This is a valuable resource for cancer researchers, oncologists, graduate students, urologists and biomedical researchers who need to understand more about liquid biopsy and its use for urogenital cancers. - Presents an overview on liquid biopsy techniques and their applications in cancer diagnosis - Explains how to extract circulating tumor DNA, RNA and circulating tumor cells and extracellular vehicles from blood samples to identify the urology cancers, including testis, prostate, bladder and kidney - Includes several images and schematic diagrams that illustrate content and facilitate its comprehension
Author: Daniel M. Trifiletti
Publisher: Springer
Published: 2019-01-22
Total Pages: 500
ISBN-13: 3319968092
DOWNLOAD EBOOKThis book provides a quick reference guide for clinicians in radiation oncology. It is designed to be an intuitive and easily reviewed study guide for board or maintenance of certification examinations, as well as a quick reference for residents and established radiation oncologists who need a refresher. The text begins with a general pearls chapter that radiation oncologists should consider in all aspects of their practice, including cancer visibility, dosing, counseling recommendations, and toxicity management. The subsequent chapters then delve into different cancer disease sites, including pediatrics, central nervous system, head and neck, thoracic, breast, gastrointestinal, gynecologic, genitourinary, hematologic, soft tissue, palliative, and radiophysics/radiobiology. Within each chapter, each disease and its recommended approach is then summarized in only a few pages, allowing a focus on the most essential information. Bullet points, figures, tables, and images make for an intuitive reader experience. Recommendations are taken from the American Society for Radiation Oncology (ASTRO), the European Society for Radiation Oncology (ESTRO), and the National Comprehensive Cancer Network (NCCN). Planning guides for imaging, diagnosis, and staging offer readers a starting point in approaching each patient based on disease origin, and dosing guidelines then detail consideration for treatment methods. Each chapter additionally includes disease-specific pearls and key points to test the knowledge reviewed in the chapters. Experts in the disease sites from the United States serve as senior authors on each chapter. The authors include all diseases associated with radiation oncology training to ensure a comprehensive resource for exam studying and clinical care. Residents, trainees, and established radiation oncologists find this an ideal study resource for both board and certification exams, as well as an easily accessible aid during practice.
Author: Moulay Mustapha Ennaji
Publisher: Academic Press
Published: 2022-10-07
Total Pages: 500
ISBN-13: 0323854974
DOWNLOAD EBOOKImmunological Implications and Molecular Diagnostics of Genitourinary Cancer updates on recent accomplishments, unifying concepts, and future challenges in the study of tumor-associated immune cells, emphasizing genitourinary cancers. The presence of inflammatory immune cells in human tumors raise a fundamental question: How do cancer cells avoid destruction by immune attack? In principle, tumor development can be controlled by cytotoxic innate and adaptive immune cells, however, as tumors develop from neoplastic tissue to clinically detectable tumors, cancer cells evolve different mechanisms. This book covers research on the immunological implications of genitourinary cancer with a comprehensive view, especially surrounding diagnosis and cellular mechanisms. - Discusses the impact of the immune system on the initiation, progression and treatment of cancer - Provides insights on the important role of the suppressor genes and oncogenes in genitourinary cancers - Shows the advantages of combining clinical issues of urologic cancers with immunological techniques, like immunohistochemistry and immunofluorescence - Demonstrates the implications genitourinary cancer has on the human innate immune system
Author: International Agency for Research on Cancer
Publisher: IARC
Published: 2004
Total Pages: 355
ISBN-13: 9283224159
DOWNLOAD EBOOKThis new volume in the WHO series on histological and genetic typing of human tumors covers tumors of the kidney, the urinary system, the prostate, the testis and paratesticular tissue and the penis. Each entity is extensively discussed with information on clinicopathological, epidemiological, immunophenotypic and genetic aspects of these diseases. This book is an authoritative, concise reference, prepared by 131 authors from 22 countries. It contains more than 800 color photographs, numerous MRIs, ultrasound images, CT scans, charts and 3000 references.This book is in the series commonly referred to as the "Blue Book" series."Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs"Contributors:: Dr Lauri A. Aaltonen, Dr Ferran Algaba, Dr William C. Allsbrook Jr., Dr Isabel Alvarado-Cabrero, Dr Mahul B. Amin, Dr Pedram Argani, Dr Hans Arnholdt, Dr Alberto G. Ayala, Dr Sheldon Bastacky, Dr Louis R. Begin, Dr Athanase Billis, Dr Liliane Boccon-Gibod, Dr Stephen M. Bonsib, Dr Christer Busch, Dr Paul Cairns, Dr Liang Cheng, Dr John Cheville, Dr Carlos Cordon-Cardo, Dr Antonio L. Cubilla, Dr Ivan Damjanov, Dr Charles J. Davis, Dr Angelo M. De Marzo, Dr Louis P. Dehner, Dr Brett Delahunt, Dr Gonzague De Pinieux, Dr P. Anthony Di Sant agnese, Dr Joakim Dillner, Dr John N. Eble, Dr Diana M. Eccles, Dr Lars Egevad, Dr M.N. El-Bolkainy, Dr Jonathan I. Epstein, Dr John F. Fetsch, Dr Masakuni Furusato, Dr Thomas Gasser, Dr William L. Gerald, Dr A. Geurts Van Kessel, Dr David J. Grignon, Dr Kenneth Grigor, Dr Jay L. Grosfeld, Dr Louis Guillou Dr Seife Hailemariam, Professor Ulrike Maria Hamper, Dr Arndt Hartmann, Dr Tadashi Hasegawa, Dr Axel Heidenreich, Dr Philipp U. Heitz, Dr Burkhard Helpap, Dr Riitta Herva, Professor Ferdinand Hofstadter, Professor Simon Horenblas, Dr Peter A. Humphrey, Dr Kenneth A. Iczkowski, Dr Grete Krag Jacobsen, Dr Sonny L. Johansson, Dr Michael A. Jones, Dr Peter A. Jones, Dr George W. Kaplan, Dr Charles E. Keen, Dr Kyu Rae Kim, Dr Maija Kiuru, Dr Paul Kleihues, Dr Margaret A. Knowles, Dr Gyula Kovacs, Dr Marc Ladanyi, Dr Virpi Launonen, Dr Ivo Leuschner, Dr Howard S. Levin, Dr W. Marston Linehan, Dr Leendert H.J. Looijenga, Dr Antonio Lopez-Beltran, Dr J. Carlos Manivel, Dr Guido Martignoni, Dr Alexander Marx, Dr David G. Mcleod, Dr L. Jeffrey Medeiros, Dr Maria J. Merino, Dr Helen Michael, Dr Markku Miettinen, Dr Holger Moch, Dr Henrik Moller, Dr Rodolfo Montironi, Dr F. Kash Mostofi, Dr Hartmut P.H. Neumann, Dr Manuel Nistal, Dr Lucien Nochomovitz, Dr Esther Oliva, Dr Tim D. Oliver, Dr J. Wolter Oosterhuis, Dr Attilio Orazi, Dr Chin-Chen Pan, Dr Ricardo Paniagua, Dr David M. Parham, Dr D. Max Parkin, Dr M. Constance Parkinson, Dr Christian P. Pavlovich, Dr Elizabeth J. Perlman, Dr Paola Pisani, Dr Andrew A. Renshaw, Dr Victor E. Reuter, Dr Jae Y. Ro, Professor Mark A. Rubin, Dr H. Gil Rushton, Dr Wael A. Sakr, Dr Hemamali Samaratunga, Dr Guido Sauter, Dr Paul F. Schellhammer, Dr Bernd J. Schmitz-Drager, Dr Mark Philip Schoenberg, Dr Isabell A. Sesterhenn, Dr David Sidransky, Dr Ronald Simon, Dr Leslie H. Sobin, Dr Poul H. B. Sorensen, Dr John R. Srigley, Dr Stephan Storkel, Dr Aleksander Talerman, Dr Pheroze Tamboli, Dr Puay H. Tan, Dr Bernard Tetu, Dr Kaori Togashi, Dr Lawrence True, Dr Jerzy E. Tyczynski, Dr Thomas M. Ulbright, Dr Eva Van Den Berg, Dr Theo H. Van Der Kwast, Dr Annick Vieillefond, Dr Geo Von Krogh, Dr Thomas Wheeler, Dr Paula J. Woodward, Dr Ximing J. Yang, Dr Berton Zbar"
Author: Hui Dai
Publisher: Frontiers Media SA
Published: 2024-04-02
Total Pages: 374
ISBN-13: 2832547109
DOWNLOAD EBOOKGenitourinary tumors consist of a large variety of malignancies located in the urinary and the reproductive systems, mainly including prostate cancer, bladder cancer, and renal tumors. Apart from surgeries, various systemic treatments have been used for the whole-course management of genitourinary tumors, including radiation therapy, chemotherapy, and hormonal therapy. However, the characteristics of progression, metastasis, and drug resistance deriving from tumors require and breed novel treatments. Furthermore, exploring biomarkers of genitourinary tumors at the early stage is also beneficial to strengthen the management of patients with tumors. Additionally, the diagnostic and prognostic value of the potential biomarkers for immunotherapy and combined therapy of genitourinary tumors are underexplored. On the basis of precision treatments, the advent of immune-based therapies, including immune checkpoint inhibitors (ICIs, antibodies targeting PD-L1 /PD-1 and CTLA-4 pathways), tumor vaccines, and other therapies, has extended the scope of treatment modalities. FDA has until now approved the clinical application of immune checkpoint inhibitors in a wide range of diseases including some types of genitourinary tumors, whereas not all patients with genitourinary tumors are suitable for immune-based therapies, therefore, the understanding of its underlying mechanism is key to develop effective treatments based on current ICI-based immunotherapy.
Author: Rodolfo Montironi
Publisher: Frontiers Media SA
Published: 2019-07-31
Total Pages: 79
ISBN-13: 2889459292
DOWNLOAD EBOOKThe identification of effective biomarkers has becoming a major focus in cancer research, mainly due to the necessity of selecting potentially responsive patients in order to improve their outcomes, as well as to reduce the toxicity and costs related to ineffective treatments. In genitourinary tumors, the lack of biomarkers does not allow for the development of personalized strategies for a single patient, thus representing a major goal in this field. This eBook includes the description of these emerging techniques and identify the most promising biomarkers in genitourinary tumors.
Author: Axel S. Merseburger
Publisher: Springer
Published: 2019-08-21
Total Pages: 870
ISBN-13: 9783319426228
DOWNLOAD EBOOKThis comprehensive and timely textbook covers all aspects of the evidence-based management of genitourinary cancers and explains the fundamental principles underlying the available diagnostic and treatment approaches, including chemotherapy, radiotherapy, immunotherapy, and surgery. For each type of cancer – prostate, bladder, renal, testicular, and penile, plus rare urologic malignancies – clinical presentation, diagnosis, and treatment strategies are described in detail and information is provided on etiology, epidemiology, risk factors, and pathology, including TNM classification. Careful attention is also devoted to the complications that may be encountered when treating urologic malignancies and to the management of these complications. The text is complemented by the inclusion of numerous high-definition photographs and illustrations. Urologic Oncology will be a valuable reference and source of guidance for all oncologists, urologists and practitioners in related disciplines who treat patients with urologic cancers.
Author: Adam Feldman
Publisher: Elsevier Health Sciences
Published: 2022-11-24
Total Pages: 177
ISBN-13: 032394020X
DOWNLOAD EBOOKIn this issue of Urologic Clinics of North America, guest editor Dr. Adam Feldman brings his considerable expertise to the topic of Biomarkers in Urology. The use of biomarkers in clinical practice can range from screening, to refined detection in an at-risk population, to risk stratification following diagnosis, to prognostication following therapy. A better understanding of tumor biology and genetic heterogeneity will lead clinicians to adopt clinical paradigms that utilize sequences of biomarker assessments. In this issue, key experts help you remain at the forefront of the care of urologic malignancies by providing a timely update on emerging biomarkers in urology. - Contains 15 practice-oriented topics including biomarkers in pediatric urology; unleashing the urinary microbiome in benign urologic disease; biomarkers for detection and assessment of clinically significant prostate cancer; biomarkers in testicular cancer: classic tumor markers and beyond; and more. - Provides in-depth clinical reviews on biomarkers in urology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.